At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large and diverse pipeline with the potential to impact cancer and orphan diseases through our single domain antibody platform technology. Single domain antibodies (sdAbs) provide a small, simple, modular target binding domain that can be combined in a variety of ways to meet specific needs of unique biological targets. Our sdAb-based therapeutic candidates have been designed to interface with the biology of each target antigen, and can be readily manufactured at high yields with established processes. We have created various multivalent and multispecific therapeutic formats that are each designed to achieve unique functions, including the ability to:
- effectively cluster receptors with precisely defined valency;
- simultaneously engage multiple antigens or epitopes;
- combine synergistic functions in a single molecule; and
- restrict therapeutic activity to the tumor microenvironment or other biologically distinct tissue.
- effectively cluster receptors with precisely defined valency;
- simultaneously engage multiple antigens or epitopes;
- combine synergistic functions in a single molecule; and
- restrict therapeutic activity to the tumor microenvironment or other biologically distinct tissue.
Location: United States
Employees: 51-200
Total raised: $40M
Founded date: 2010
Investors 2
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | RA Capital... | racap.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.05.2019 | IPO | $40M | - |
Mentions in press and media 20
| Date | Title | Description |
| 01.02.2026 | Llamas are big pharma’s secret weapon to find new drugs | Getting your Trinity Audio player ready... By Lisa Pham, Bloomberg News One llama is sprawled on the grass with its neck craned, basking in a patch of sunshine. Another stands on a dirt hill, ears flattened defiantly. A third rushes to gree... |
| 13.03.2024 | SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KAMN, JNPR, INBX | - |
| 05.01.2022 | Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data | SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced initial results from Part 3 (combination dose escalatio... |
| 02.12.2021 | Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma | SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the U.S. Food and Drug Administration, or FDA, has... |
| 03.11.2021 | Inhibrx Announces Presentations at SITC 2021 | SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the Company will be presenting three poster... |
| 01.11.2021 | Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences | SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the Company will be presenting at the Conne... |
| 13.09.2021 | Inhibrx : Announces Participation in Upcoming Investor Conference | SAN DIEGO, Sept. 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be present... |
| 13.09.2021 | Inhibrx Announces Participation in Upcoming Investor Conference | |
| 21.06.2021 | Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with... | |
| 21.06.2021 | INHIBRX, INC. Inhibrx : Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Lo... | SAN DIEGO, June 21, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced initiation of a potential registration-enabling Phase 2 study of INBRX-109 in conventional ... |
Show more